Holen Sie sich die Stockscreener-App
0.7147
2.10%
0.0147
Handel nachbörslich:
.72
0.0053
+0.74%
Schlusskurs vom Vortag:
$0.70
Offen:
$0.7
24-Stunden-Volumen:
329.09K
Relative Volume:
0.28
Marktkapitalisierung:
$37.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.22M
KGV:
-0.2415
EPS:
-2.96
Netto-Cashflow:
$-74.41M
1W Leistung:
+8.26%
1M Leistung:
-2.64%
6M Leistung:
-44.60%
1J Leistung:
-10.09%
1-Tages-Spanne:
$0.69
$0.7249
1-Wochen-Bereich:
$0.63
$0.7249
52-Wochen-Spanne:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Firmenname
Xilio Therapeutics Inc
Sektor
Branche
Telefon
617-833-1027
Adresse
828 WINTER STREET, WALTHAM
Vergleichen Sie XLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.7147 | 36.25M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2022-12-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-16 | Eingeleitet | Guggenheim | Buy |
| 2021-11-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-16 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
Heatmap analysis for Xilio Therapeutics Inc. and competitorsTrade Plan With Low Risk High Return - Newser
Brokers Issue Forecasts for XLO Q2 Earnings - Defense World
Advanced analytics toolkit walkthrough for Xilio Therapeutics Inc.Free Stock Market Watch With Alerts - Newser
Analyzing drawdowns of Xilio Therapeutics Inc. with statistical toolsAsset Allocation Summary With Future Outlook - Newser
Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating, Sets Price Target of $2.00 - AInvest
How to use Fibonacci retracement on Xilio Therapeutics Inc.Momentum Entry Alerts with Risk Control - Newser
Using Bollinger Bands to evaluate Xilio Therapeutics Inc.Free High Conviction Intraday Stock Signals - Newser
Leerink Partners Maintains Xilio Therapeutics(XLO.US) With Buy Rating, Maintains Target Price $2 - 富途牛牛
Leerink Partners Begins Coverage on Xilio Therapeutics (NASDAQ:XLO) - Defense World
Xilio Therapeutics (XLO) Projected to Post Quarterly Earnings on Thursday - Defense World
Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating - AInvest
Leerink Partners Initiates Xilio Therapeutics(XLO.US) With Buy Rating, Announces Target Price $2 - 富途牛牛
Xilio Therapeutics shares rise 4.95% premarket after Leerink Partners initiates coverage with an Outperform rating. - AInvest
Leerink Partners Initiates Xilio Therapeutics at Outperform With $2 Price Target - MarketScreener
Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating - Investing.com India
Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Xilio Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
When is Xilio Therapeutics Inc. stock expected to show significant growthCapitalize on market shifts before others do - Jammu Links News
What institutional investors are buying Xilio Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News
What makes Xilio Therapeutics Inc. stock price move sharplyAchieve consistent profits with smart trading - Jammu Links News
Is Xilio Therapeutics Inc. a growth stock or a value stockAchieve rapid wealth accumulation through smart investing - Jammu Links News
Why is Xilio Therapeutics Inc. stock attracting strong analyst attentionAccelerated wealth expansion - Jammu Links News
What are Xilio Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - Jammu Links News
What is Xilio Therapeutics Inc. company’s growth strategyIdentify winners with top-tier analysis - Jammu Links News
What are the latest earnings results for Xilio Therapeutics Inc.Maximize returns with effective portfolio management - Jammu Links News
Xilio Therapeutics Inc. Stock Analysis and ForecastNavigate the market with precision tools - Jammu Links News
MACD Cross Could Confirm Trend in Xilio Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What is the risk reward ratio of investing in Xilio Therapeutics Inc. stockMarket Forecast Data Feed From AI Tools - Jammu Links News
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Why Xilio Therapeutics Inc. stock attracts strong analyst attentionVolume Based Entry Signal Outlook - beatles.ru
Will Xilio Therapeutics Inc. rebound enough to break evenRisk Adjusted Technical Entry Plan Gains Followers - metal.it
Breakout Traders Target Xilio Therapeutics Inc. on Recovery SetupCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Xilio Therapeutics Inc. Forms Bullish Flag — Upside AheadReal-Time Market Sentiment Tracking Gains Momentum - metal.it
Bristol Myers Squibb and Bain Capital Form New Immunology Company - MarketWatch
Does Xilio Therapeutics Inc. stock perform well during market downturnsTremendous growth opportunities - Jammu Links News
How does Xilio Therapeutics Inc. generate profit in a changing economyHigh-yield investments - Jammu Links News
Published on: 2025-07-28 02:43:54 - jammulinksnews.com
How Resilient Is Xilio Therapeutics Inc. Stock During Economic DownturnsMassive Upside Selection - Newser
What analysts say about Xilio Therapeutics Inc. stockHigh-yield capital appreciation - PrintWeekIndia
What risks could impact Xilio Therapeutics Inc. stock performanceDynamic investment growth - jammulinksnews.com
Does Xilio Therapeutics Inc. stock pay reliable dividendsRecord-breaking gains - jammulinksnews.com
What makes Xilio Therapeutics Inc. stock attractive to long term investorsRapid wealth accumulation - jammulinksnews.com
Is Xilio Therapeutics Inc. a good long term investmentOverwhelming profit margins - jammulinksnews.com
Finanzdaten der Xilio Therapeutics Inc-Aktie (XLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):